Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia

Yuan, Xiuxia; Zhang, Peifen; Wang, Yaping; Liu, Yafei; Xue, Ling; Kumar, Bachoo Upshant; Hei, Gangrui; Lv, Luxian; Huang, Xu‐Feng; Fan, Xiaoduo; Song, Xueqin

doi:10.1016/j.schres.2018.05.017

Cited by 123 publications

(127 citation statements)

References 52 publications

Supporting

Mentioning

116

Contrasting

Unclassified

Order By: Relevance

“…Patient groups also differed in age, stage of illness, and treatment status. Indeed, antipsychotics have significant anti-commensal activity (22), and in rodents, olanzapine has been shown to elevate Firmicutes and decrease Bacteroidetes (23,24), which was paralleled in human antipsychotic trials (25,26), although not universally (27). These results bear resemblance to some of those reported in Table 1, and suggest that the microbiome was affected by treatment status.…”

Section: Evidence For Dysbiosis In Schizophreniamentioning

confidence: 52%

The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications

et al. 2020

View full text Add to dashboard Cite

Section: Evidence For Dysbiosis In Schizophreniamentioning

confidence: 52%

The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications

et al. 2020

View full text Add to dashboard Cite

“…Little is known about the effects of AAPs on the microbiota; however, a small body of evidence suggests they cause severe adverse effects. Olanzapine and risperidone induced an increase in Firmicutes and a decrease in Bacteroidetes, as well as metabolic alterations as a result of a shift toward a potentially obesogenic bacterial profile associated with short-chain fatty acids and inflammation in adults (348), children (349,350), and rodents (351). These changes were also gender-dependent (349,352,353), with females showing a higher pro-inflammatory cytokine (IL-8 and IL-1β) response in circulation and macrophage infiltration; still, microbiota dysbiosis was equally present in males and females.…”

Section: Microbiotamentioning

confidence: 99%

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

et al. 2020

View full text Add to dashboard Cite

Atypical antipsychotics (AAP) or second-generation antipsychotics are the clinical option for schizophrenia treatment during acute psychoses, but they are also indicated for maintenance during lifetime, even though they are being used for other psychiatric conditions in clinical practice such as affective disorders and autism spectrum disorder, among others. These drugs are differentiated from typical antipsychotics based on their clinical profile and are a better choice because they cause fewer side effects regarding extrapyramidal symptoms (EPS). Even though they provide clear therapeutic benefits, AAP induce peripheral effects that trigger phenotypic, functional, and systemic changes outside the Central Nervous System (CNS). Metabolic disease is frequently associated with AAP and significantly impacts the patient's quality of life. However, other peripheral changes of clinical relevance are present during AAP treatment, such as alterations in the immune and endocrine systems as well as the intestinal microbiome. These less studied alterations also have a significant impact in the patient's health status. This manuscript aims to revise the peripheral immunological, endocrine, and intestinal microbiome changes induced by AAP consumption recommended in the clinical guidelines for schizophrenia and other psychiatric disorders.

show abstract

“…was not significantly different between FEP and NC groups. Yuan et al (2018) reported reduced numbers of Bifidobacterium spp., Escherichia coli, and Lactobacillus spp. and increased numbers of Clostridium coccoides group in FEP compared to NCs, while Schwarz et al (2018) found no differences in bacterial numbers between FEP and NCs.…”

Section: Cross-sectional Findingsmentioning

confidence: 99%

“…Bifidobacterium spp. was correlated with lower serum low-density lipoprotein (LDL), while Escherichia coli correlated with lower serum triglycerides and high-sensitivity C-reactive protein (Yuan et al, 2018). Finally, one study explored possible functional pathways using PICRUSt to infer genetic potentials based on 16S sequences, with no differences in any KEGG pathways to three levels (He et al, 2018).…”

Section: Cross-sectional Findingsmentioning

confidence: 99%

Gut microbiome in serious mental illnesses: A systematic review and critical evaluation

Nguyen

Hathaway

Kościółek

et al. 2021

Schizophrenia Research

View full text Add to dashboard Cite

Schizophrenia and bipolar disorder (BD) are associated with debilitating psychiatric and cognitive dysfunction, worse health outcomes, and shorter life expectancies. The pathophysiological understanding of and therapeutic resources for these neuropsychiatric disorders are still limited. Humans harbor over 1000 unique bacterial species in our gut, which have been linked to both physical and mental/cognitive health. The gut microbiome is a novel and promising avenue to understand the attributes of psychiatric diseases and, potentially, to modify them. Building upon our previous work, this systematic review evaluates the most recent evidence of the gut microbiome in clinical populations with serious mental illness (SMI). Sixteen articles that met our selection criteria were reviewed, including cross-sectional cohort studies and longitudinal treatment trials. All studies reported alterations in the gut microbiome of patients with SMI compared to non-psychiatric comparison subjects (NCs), and beta-diversity was consistently reported to be different between schizophrenia and NCs. Ruminococcaceae and Faecalibacterium were relatively decreased in BD, and abundance of Ruminococcaceae was reported across several investigations of SMI to be associated with better clinical characteristics. Lactic acid bacteria were relatively more abundant in SMI and associated with worse clinical outcomes. There was very limited evidence for the efficacy of probiotic or prebiotic interventions in SMI. As microbiome research in psychiatry is still nascent, the extant literature has several limitations. We critically evaluate the current data, including experimental approaches. There is a need for more unified methodological standards in order to arrive at robust biological understanding of microbial contributions to SMI.

show abstract

Changes in metabolism and microbiota after 24-week risperidone treatment in drug naïve, normal weight patients with first episode schizophrenia

Cited by 123 publications

References 52 publications

The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications

The Gut Microbiome and Schizophrenia: The Current State of the Field and Clinical Applications

Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics

Gut microbiome in serious mental illnesses: A systematic review and critical evaluation

Contact Info

Product

Resources

About